Inventor · disambiguated record
William Strohl
Also filed as: STROHL WILLIAM · STROHL WILLIAM R
31 granted patents·7 pending applications·239 citations·filing 1996–2022
97Inventor score
Top patents by PatentIndex Score
38 records- 0196US10053513B2Antibody Fc mutants with ablated effector functionsJANSSEN BIOTECH INC·Filed 2015·Granted Aug 21, 2018·15 cites·5 claims
- 0296US9637549B2Antibody Fc mutants with ablated effector functionsJANSSEN BIOTECH INC·Filed 2015·Granted May 2, 2017·8 cites·1 claims
- 0396US8961967B2Antibody Fc mutants with ablated effector functionsSTROHL WILLIAM·Filed 2010·Granted Feb 24, 2015·56 cites·10 claims
- 0492US7780963B2Anti-ADDL antibodies and uses thereofMERCK & CO INC·Filed 2005·Granted Aug 24, 2010·25 cites·14 claims
- 0591US10894836B2Antibody Fc mutants with ablated effector functionsJANSSEN BIOTECH INC·Filed 2018·Granted Jan 19, 2021·7 cites·5 claims
- 0691US9644023B2Compositions and methods for phagocyte delivery of anti-staphylococcal agentsUNIV NEW YORK·Filed 2014·Granted May 9, 2017·19 cites·24 claims
- 0791US7754213B2High affinity antibody antagonists of interleukin-13 receptor alpha 1MERCK & CO INC·Filed 2007·Granted Jul 13, 2010·13 cites·7 claims
- 0890US8871204B2Active protease-resistant antibody FC mutantsBREZSKI RANDALL·Filed 2012·Granted Oct 28, 2014·17 cites·31 claims
- 0987US7811563B2Anti-addl antibodies and uses thereofUNIV NORTHWESTERN·Filed 2005·Granted Oct 12, 2010·9 cites·14 claims
- 1086US7700099B2Non-immunostimulatory antibody and compositions containing the sameMERCK & CO INC·Filed 2006·Granted Apr 20, 2010·24 cites·4 claims
- 1184US7731962B2Anti-ADDL monoclonal antibody and use thereofMERCK & CO INC·Filed 2006·Granted Jun 8, 2010·8 cites·12 claims
- 1281US8383113B2Anti-ADDL antibodies and uses thereofUNIV NORTHWESTERN·Filed 2012·Granted Feb 26, 2013·4 cites·12 claims
- 1379US11096998B2Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereofJANSSEN BIOTECH INC·Filed 2017·Granted Aug 24, 2021·1 cites·2 claims
- 1479US9371388B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2013·Granted Jun 21, 2016·2 cites·4 claims
- 1579US2023212252A1RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofBIOAGE LABS INC·Filed 2022·Application pending·0 cites
- 1678US8785605B2Humanized IL-25 antibodiesALMAGRO JUAN CARLOS·Filed 2011·Granted Jul 22, 2014·5 cites·13 claims
- 1777US11535661B2RAGE fusion proteins with improved stability and ligand binding affinity and uses thereofBIOAGE LABS INC·Filed 2021·Granted Dec 27, 2022·0 cites·18 claims
- 1876US9777062B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2016·Granted Oct 3, 2017·1 cites·10 claims
- 1976US8889138B2Anti-ADDL antibodies and uses thereofACTON PAUL·Filed 2010·Granted Nov 18, 2014·3 cites·12 claims
- 2076US8568722B2High affinity antibody antagonists of interleukin-13 receptor alpha 1NASH ANDREW DONALD·Filed 2010·Granted Oct 29, 2013·2 cites·2 claims
- 2176US8128930B2Anti-ADDL antibodies and uses thereofACTON PAUL·Filed 2010·Granted Mar 6, 2012·3 cites·13 claims
- 2276US8105593B2Anti-ADDL monoclonal antibody and use thereofKINNEY GENE·Filed 2010·Granted Jan 31, 2012·2 cites·12 claims
- 2375US8420093B2Anti-ADDL monoclonal antibody and use thereofKINNEY GENE·Filed 2012·Granted Apr 16, 2013·2 cites·12 claims
- 2474US8207304B2Antibody antagonists of interleukin-13 receptor α1NASH ANDREW DONALD·Filed 2007·Granted Jun 26, 2012·2 cites·6 claims
- 2571US10913784B2RAGE fusion proteins with improved stability and ligand binding affinity and uses thereofBIOAGE LABS INC·Filed 2019·Granted Feb 9, 2021·0 cites·15 claims
- 2671US8613925B2Anti-IL-13Rα1 antibodies and their uses thereofNASH ANDREW DONALD·Filed 2007·Granted Dec 24, 2013·1 cites·9 claims
- 2769US2021188940A1RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofBIOAGE LABS INC·Filed 2020·Application pending·0 cites
- 2867US2021155711A1Antibody Fc Mutants with Ablated Effector FunctionsJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2966US7294646B2Maxi-k channel blockers, methods of use and process for making the sameMERCK & CO INC·Filed 2003·Granted Nov 13, 2007·3 cites·6 claims
- 3064US10106617B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2017·Granted Oct 23, 2018·0 cites·12 claims
- 3163US9611328B2Active protease-resistant antibody FC mutantsJANSSEN BIOTECH INC·Filed 2014·Granted Apr 4, 2017·0 cites·12 claims
- 3261US2022031822A1Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereofJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 3358US2017204193A1Antibody Fc Mutants with Ablated Effector FunctionsJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 3457US2022251191A1Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteinsARCH ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 3556US10087243B2Compositions and methods for phagocyte delivery of anti-staphylococcal agentsUNIV NEW YORK·Filed 2017·Granted Oct 2, 2018·0 cites·23 claims
- 3643US2005239787A1Novel maxi-k channel blockers, methods of use and process for making the sameGOETZ MICHAEL A·Filed 2003·Application pending·0 cites
- 3739US5976830AMethods of producing doxorubicinUNIV OHIO STATE RES FOUND·Filed 1996·Granted Nov 2, 1999·5 cites·17 claims
- 3837US5962293AMethods of producing doxorubicinOHIO STATE RES FOUND·Filed 1998·Granted Oct 5, 1999·2 cites·4 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →